Literature DB >> 26732597

GWAS-Linked Loci and Neuroimaging Measures in Alzheimer's Disease.

Jie-Qiong Li1, Hui-Fu Wang2, Xi-Chen Zhu2, Fu-Rong Sun1, Meng-Shan Tan1, Chen-Chen Tan1, Teng Jiang3, Lan Tan4,5, Jin-Tai Yu6,7.   

Abstract

Recently, 19 susceptibility loci for Alzheimer's disease (AD) had been identified through AD genome-wide association studies (GWAS) meta-analysis. However, how they influence the pathogenesis of AD still remains largely unknown. We studied those loci with six MRI measures, abnormal glucose metabolism, and β-amyloid (Aβ) deposition on neuroimaging in a large cohort from Alzheimer's Disease Neuroimaging Initiative (ADNI) database in order to provide clues of the mechanisms through which these genetic variants might be acting. As a result, single nucleotide polymorphisms (SNPs) at rs983392 within MS4A6A and rs11218343 within SOLR1 were both associated with the percentage of increase in the volume of left inferior temporal regions in the follow-up study. Meanwhile, rs11218343 at SORL1 and rs6733839 at BIN1 was associated with rate of volume change of left parahippocampal and right inferior parietal, respectively. Moreover, rs6656401 at CR1 and rs983392 at MS4A6A were both associated with smaller volume of right middle temporal at baseline. However, in addition to the APOE locus, we did not detect any influence on glucose metabolism and Aβ deposition. APOE ε4 allele was associated with almost all measures. Altogether, five loci (rs6656401 at CR1, rs983392within MS4A6A, rs11218343 at SORL1, rs6733839 at BIN1, and APOE ε4) have been detected to be associated with one or a few established AD-related neuroimaging measures.

Entities:  

Keywords:  Alzheimer’s disease; Aβ deposition; Brain structure; Genome-wide association studies; Glucose metabolism

Mesh:

Year:  2016        PMID: 26732597     DOI: 10.1007/s12035-015-9669-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  26 in total

Review 1.  Novel disease-modifying therapies for Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry.

Authors:  G B Karas; E J Burton; S A R B Rombouts; R A van Schijndel; J T O'Brien; P h Scheltens; I G McKeith; D Williams; C Ballard; F Barkhof
Journal:  Neuroimage       Date:  2003-04       Impact factor: 6.556

3.  Loss of apolipoprotein E receptor LR11 in Alzheimer disease.

Authors:  Clemens R Scherzer; Katrin Offe; Marla Gearing; Howard D Rees; Guofu Fang; Craig J Heilman; Chica Schaller; Hideaki Bujo; Allan I Levey; James J Lah
Journal:  Arch Neurol       Date:  2004-08

4.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease.

Authors:  Christine Fennema-Notestine; Donald J Hagler; Linda K McEvoy; Adam S Fleisher; Elaine H Wu; David S Karow; Anders M Dale
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

Review 5.  Genome-wide association studies in Alzheimer disease.

Authors:  Stephen C Waring; Roger N Rosenberg
Journal:  Arch Neurol       Date:  2008-03

6.  Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Authors:  K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

Review 7.  Complement receptor 1 (CR1) and Alzheimer's disease.

Authors:  Helen Crehan; Patrick Holton; Selina Wray; Jennifer Pocock; Rita Guerreiro; John Hardy
Journal:  Immunobiology       Date:  2011-07-23       Impact factor: 3.144

8.  Multilocus genetic profiling to empower drug trials and predict brain atrophy.

Authors:  Omid Kohannim; Xue Hua; Priya Rajagopalan; Derrek P Hibar; Neda Jahanshad; Joshua D Grill; Liana G Apostolova; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage Clin       Date:  2013-06-13       Impact factor: 4.881

9.  Overrepresentation of glutamate signaling in Alzheimer's disease: network-based pathway enrichment using meta-analysis of genome-wide association studies.

Authors:  Eduardo Pérez-Palma; Bernabé I Bustos; Camilo F Villamán; Marcelo A Alarcón; Miguel E Avila; Giorgia D Ugarte; Ariel E Reyes; Carlos Opazo; Giancarlo V De Ferrari
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

10.  Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood.

Authors:  Petroula Proitsi; Sang Hyuck Lee; Katie Lunnon; Aoife Keohane; John Powell; Claire Troakes; Safa Al-Sarraj; Simon Furney; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Angela Hodges
Journal:  Neurobiol Aging       Date:  2013-09-21       Impact factor: 4.673

View more
  10 in total

1.  A Longitudinal Imaging Genetics Study of Neuroanatomical Asymmetry in Alzheimer's Disease.

Authors:  Christian Wachinger; Kwangsik Nho; Andrew J Saykin; Martin Reuter; Anna Rieckmann
Journal:  Biol Psychiatry       Date:  2018-05-09       Impact factor: 13.382

2.  The impact of Alzheimer's disease susceptibility loci on lateral ventricular surface morphology in older adults.

Authors:  Shan Li; Na An; Nan Chen; Yin Wang; Lin Yang; Yalin Wang; Zhijun Yao; Bin Hu
Journal:  Brain Struct Funct       Date:  2022-01-14       Impact factor: 3.270

Review 3.  The relationship of early- and late-onset Alzheimer's disease genes with COVID-19.

Authors:  Seda Sirin; Serap Nigdelioglu Dolanbay; Belma Aslim
Journal:  J Neural Transm (Vienna)       Date:  2022-04-16       Impact factor: 3.850

Review 4.  Toward precision medicine in neurological diseases.

Authors:  Lin Tan; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2016-03

5.  [Verification of a sporadic Alzheimer disease model in SORL1 gene knockout mice].

Authors:  Fang-Bo Lin; Xin Liu; Jing-Wen Xie; Jing Luo; Xia-Lu Feng; De-Ren Hou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

6.  The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism.

Authors:  Eddie Stage; Tugce Duran; Shannon L Risacher; Naira Goukasian; Triet M Do; John D West; Holly Wilhalme; Kwangsik Nho; Meredith Phillips; David Elashoff; Andrew J Saykin; Liana G Apostolova
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-19

7.  MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures.

Authors:  Jing Ma; Wei Zhang; Lin Tan; Hui-Fu Wang; Yu Wan; Fu-Rong Sun; Chen-Chen Tan; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2016-09-13

8.  Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration.

Authors:  Meng-Shan Tan; Yu-Xiang Yang; Wei Xu; Hui-Fu Wang; Lin Tan; Chuan-Tao Zuo; Qiang Dong; Lan Tan; John Suckling; Jin-Tai Yu
Journal:  Alzheimers Res Ther       Date:  2021-01-08       Impact factor: 6.982

9.  Polygenic Hazard Score Associated Multimodal Brain Networks Along the Alzheimer's Disease Continuum.

Authors:  Kaicheng Li; Zening Fu; Shile Qi; Xiao Luo; Qingze Zeng; Xiaopei Xu; Peiyu Huang; Minming Zhang; Vince D Calhoun
Journal:  Front Aging Neurosci       Date:  2021-09-03       Impact factor: 5.750

10.  Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease.

Authors:  Elham Mehdizadeh; Mohammad Khalaj-Kondori; Zeinab Shaghaghi-Tarakdari; Saeed Sadigh-Eteghad; Mahnaz Talebi; Sasan Andalib
Journal:  Bioimpacts       Date:  2019-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.